Hand Function Impairment in Systemic Sclerosis: Outcomes, Mechanisms and Experience (HANDSOME)
Launched by UMC UTRECHT · Nov 10, 2023
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
The HANDSOME trial is a research study looking at how systemic sclerosis (SSc), a condition that affects the skin and organs, impacts hand function. Many people with SSc struggle with using their hands, which can make everyday tasks and work difficult. This study focuses on understanding why this happens, particularly looking at hand contractures, which are tightness and stiffness in the hands that can limit movement. By studying patients with SSc, the researchers hope to learn more about the processes that lead to these hand function issues.
To participate in this study, you need to be over 18 years old and have been diagnosed with systemic sclerosis. However, if you have certain other conditions, like diabetic cheiroarthropathy (a hand problem related to diabetes) or Dupuytren's disease (a condition causing thickening of the tissue in the palm), you won't be eligible to join. If you decide to take part, you will be part of a group that helps researchers gather important information about hand function. This could lead to better understanding and treatment options for people living with systemic sclerosis in the future. The study is currently recruiting participants, and everyone, regardless of gender, is welcome to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- Exclusion Criteria:
- • Patients with diabetic cheiroarthropathy and Dupuytren's disease, based on expert opinion
About Umc Utrecht
UMC Utrecht is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research and high-quality patient care. As a prominent sponsor of clinical trials, UMC Utrecht leverages its extensive expertise in translational medicine and collaboration with various stakeholders to advance medical knowledge and improve therapeutic outcomes. The institution emphasizes ethical conduct and rigorous scientific standards, ensuring that all research activities contribute meaningfully to the global healthcare landscape. Through its robust clinical trial infrastructure, UMC Utrecht plays a vital role in facilitating the development of new treatments and enhancing patient wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Utrecht, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported